FOSUN HEALTH Logo

Lung Cancer Overview

catalogue

Lung Cancer Overview

Lung Cancer Overview

Lung cancer found early can often be treated with cure in mind. This page explains what the disease is and how it behaves — then opens into six full guides covering symptoms, diagnosis, treatment, causes, prevention, and the questions international patients ask most.

Lung Cancer Overview
  • new lung cancer cases worldwide each year (WHO)

  • are found at a late stage — screening changes this

  • CyberKnife radiosurgery cases at our Foshan center since 2022

  • from complete records to a personalized MDT plan

What lung cancer is

Lung cancer begins when cells in the lining of the airways, or in the lung tissue itself, grow out of control and form a tumor. What makes it different from many other cancers is how little it announces itself: the inside of the lung has no pain-sensitive nerves, and the lungs hold a large functional reserve, so a tumor can reach a considerable size without causing a cough, breathlessness or any other signal.

Two practical consequences follow from that anatomy. The first is that most lung cancers are found late — worldwide, close to 70% are diagnosed only after the tumor has spread or become impossible to remove surgically. The second is the reverse of the first: when lung cancer is found early, cure becomes a realistic goal, which is why screening exists. Symptoms and screening are covered in their own guides.

A diagnosis therefore always raises two separate questions, and both must be answered before anything is decided: how far the cancer has gone (its stage) and what is driving it (its molecular profile). Modern lung cancer care is built on those two axes, not on the diagnosis alone.

Non-small cell and small cell: two diseases, two plans

The two main types of lung cancer are not close variations of one illness. They arise from different cells, grow at different speeds and respond to different treatments — which is why the first thing a pathologist determines is which type is present.

Non-small cell lung cancer (NSCLC) Small cell lung cancer (SCLC)
How common The great majority of all lung cancers A minority of cases
Growth pattern Usually slower, and more often confined to one area when found Fast-growing; spreads early, often before symptoms
Typical location Frequently the outer lung tissue. Adenocarcinoma is the most common subtype; squamous cell carcinoma and large cell carcinoma are less common Usually the central airways, close to the main bronchi
Main treatments Surgery and radiosurgery, targeted therapy, immunotherapy, chemotherapy Chemotherapy with radiotherapy; immunotherapy in selected cases
Targetable mutations Frequently present — EGFR, ALK, ROS1, MET, RET, KRAS and others Rarely targetable
Who it affects Smokers and never-smokers alike; adenocarcinoma is the most common type in never-smokers and in women Strongly linked to smoking

Adenocarcinoma deserves particular attention in Asia. It is the subtype most often found in people who have never smoked, and it is more likely than other subtypes to carry a mutation that can be treated with a targeted drug. That single fact changes the first step for many patients: before any drug is chosen, the tumor should be tested.

What the stages mean

Staging describes how far the cancer has spread. It tells you what is physically possible — whether a surgeon can remove the tumor, whether the disease is confined to the chest, and whether treatment is aimed at cure or at long-term control.

Stage What it means What treatment is usually aiming for
Stage I The tumor is confined to the lung; no lymph nodes are involved Cure. Surgery, or stereotactic body radiotherapy (SBRT) with breath-tracking CyberKnife when surgery is not suitable
Stage II A larger tumor, or involvement of nearby lymph nodes on the same side Cure. Surgery, usually combined with drug therapy before or after the operation
Stage III Locally advanced — the cancer has reached lymph nodes in the centre of the chest Still curative for some patients. Chemoradiotherapy, immunotherapy, and surgery in selected cases
Stage IV The cancer has spread to the other lung, the lining of the lung, or distant organs such as bone, liver, brain or adrenal glands Long-term control. Targeted therapy, immunotherapy or chemotherapy, with radiotherapy directed at specific sites when needed

It is worth saying plainly what stage IV does and does not mean. It does mean the cancer cannot be removed by an operation. It does not mean there is nothing to do: with targeted or immunotherapy drugs, a proportion of advanced lung cancers are now managed the way a chronic illness is managed — with continuous treatment, periodic scans, and patients who return to work and family life. The number that matters is not the stage alone but which treatment the tumor will respond to.

Stage is not fixed by the first scan. If a tumor shrinks substantially with drug treatment or interventional therapy, an inoperable cancer can sometimes become operable — this is called conversion therapy, and it is one reason a case should be reviewed by a multidisciplinary panel rather than a single department.

Why molecular type matters as much as stage

Two patients can have adenocarcinoma of the same stage and need completely different drugs. The difference lies in the tumor's DNA. Molecular profiling examines the tumor tissue for driver alterations — EGFR, ALK, ROS1, MET, RET and others — and for PD-L1 expression, which indicates whether immunotherapy is likely to help.

This is why a targeted drug works only when its target is actually present, and why the test should come before the prescription rather than after it has failed. It also explains a pattern that surprises many international patients: in Asia, a markedly higher share of lung cancers in people who have never smoked — particularly in women — carry a treatable EGFR alteration than in Europe or North America. A tumor that would be treated with chemotherapy in one country can be a candidate for a daily tablet in another.

When the first targeted drug eventually stops working, the next question is what comes after it. Later-generation inhibitors, antibody–drug approaches and matched clinical trials matter here, and access to them varies considerably between countries. How we test and how treatment is chosen is set out in the diagnosis guide and the treatment guide.

Why international patients come to China for lung cancer treatment

Four practical reasons come up most often in conversations with patients and their families — none of them exotic, all of them consequential.

Volume, and the pattern recognition that comes with it

China carries close to one third of the world's lung cancer burden, with roughly 800,000 new diagnoses each year. Teams here meet this disease daily, in every stage and every molecular subtype — including the uncommon presentations that are seen only a few times a year in lower-volume centres.

The whole pathway under one roof

Low-dose CT and PET-CT imaging, endobronchial ultrasound and bronchoscopy, CT-guided biopsy, pathology, in-house NGS molecular testing, robotic surgery, breath-tracking radiosurgery and interventional oncology all sit inside the same hospital network. Diagnosis and treatment do not have to be assembled across several institutions or countries.

Earlier access to newer drugs

Later-generation EGFR and ALK inhibitors, antibody–drug approaches and mutation-matched clinical trials often enter routine use in China years before they become available in some other regions. For a patient whose first targeted drug has stopped working, that difference is not academic.

One decision, made by six specialties

Surgery, medical oncology, radiation oncology, interventional radiology, radiology and pathology review the case together and issue a single plan — within 48 hours of your records being complete — instead of a plan that depends on which department you happened to visit first.

Frequently Asked Questions

Is a lung cancer diagnosis still a terminal diagnosis?

Far less often than it used to be, and the answer now depends heavily on the type and the molecular profile rather than the diagnosis alone. Lung cancer found at stage I is frequently treated with cure as the goal. In advanced disease, targeted therapy and immunotherapy have turned some lung cancers into conditions managed long-term with patients living years on treatment. The realistic question today is not whether lung cancer can be treated, but which treatment fits your tumor.

What is the difference between the stage of lung cancer and its molecular type?

The stage describes how far the cancer has spread — it tells you what is physically possible, such as whether surgery can remove the tumor. The molecular type describes what is driving the cancer at the level of its DNA, such as an EGFR or ALK alteration, and it tells you which drug is likely to work. Two patients with the same stage can need completely different treatments, which is why both answers are needed before a plan is made.

Can I get a second opinion before deciding to travel for treatment?

Yes, and it is a reasonable first step. Send your CT or PET-CT images, your pathology report, and any molecular testing you already have. Our multidisciplinary panel reviews the records and returns a written assessment with treatment options and a preliminary plan, usually within 48 hours of receiving complete files. You can then decide about travelling, with no obligation.

How common is lung cancer in people who have never smoked?

More common than most people expect. Lung cancer in never-smokers is a recognised and substantial group worldwide, and it is not rare in Asia. These tumors are frequently adenocarcinomas and are more likely to carry a targetable mutation such as EGFR — which matters, because it means a never-smoker with a persistent symptom still deserves proper investigation rather than reassurance.

Patient Stories

Stories from our lung cancer programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Get a personalized lung cancer plan in 48 hours

Send us your CT or PET-CT images, pathology report and any molecular testing you already have. Our lung cancer panel reviews the case together and returns a written assessment with the options that apply to your stage and molecular type.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*